Phaseline

Companies › Changchun GeneScience Pharmaceutical

Changchun GeneScience Pharmaceutical: clinical trials, targets and expected readouts

22 active drug programs in 59 registered trials: 22 Phase 2, 20 Phase 1, 13 Phase 3, 4 Phase 4; Oncology, Metabolic and endocrine, Other, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Megestrol Acetate
Progesterone receptor agonist
PGRPhase 4Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia; Non-small Cell Lung Cancer; Neoadjuvant Chemotherapy; Nutrition Disorders …Dec 2026
Somatropin
Growth hormone receptor agonist
GHRPhase 4Short Bowel Syndrome (SBS) in Adults; Short Stature Children Born Small for Gestational Age (SGA); Dwarfism; Healthy …Apr 2027
Cabergoline
Dopamine D2 receptor agonist
DRD2Phase 3Hyperprolactinemia; Prolactinoma; Pituitary Neoplasms; Gynecologic Disease …Nov 2026
Leuprolide
Gonadotropin-releasing hormone receptor agonist
GNRHRPhase 3Breast Cancer Subjects–
PEG-rhGH Injection (Jintrolong®)
Recombinant human growth hormone with polyethylene glycol modification for extended half-l
GH1Phase 2Short Stature Children Born Small for Gestational Age (SGA)Dec 2026
GenSci120 150 mg–Phase 2Rheumatoid ArthritisSep 2027
GenSci048–Phase 2Uveitis; Endometriosis-related PainDec 2027
Genakumab injection
CXCL10 inhibitor monoclonal antibody
CXCL10Phase 2Systemic Sclerosis Associated Interstitial Lung Disease–
GenSci134
Growth hormone secretagogue (based on context of AGHD indication)
–Phase 1SafetyNov 2026
GenSci144 tablets
SLC6A19 transporter small molecule inhibitor
SLC6A19Phase 1PhenylketonuriaDec 2026
[14C]GS1-144–Phase 1Healthy Postmenopausal WomenDec 2026
GenSci142–Phase 1RandomizedJan 2027
GenSci136–Phase 1Autoimmune DiseaseFeb 2027
GenSci098–Phase 1SafetyMar 2027
GenSci161–Phase 1Healthy VolunteersMay 2027
GenSci128
TP53 Y220C mutant stabilizer
TP53Phase 1Solid Tumors Harboring a TP53 Y220C MutationDec 2027
GenSci140
Folate receptor alpha (FRα) targeting agent for FRα-positive advanced solid tumors
FOLR1Phase 1Advanced Solid TumorsMar 2028
GenSci139
bispecific antibody drug conjugate targeting EGFR and HER2
EGFR, HER2Phase 1Advanced Solid TumorsJul 2028
GenSci143 for injection–Phase 1Advanced Solid TumorsOct 2028
GenSci145
PIK3CA inhibitor
PIK3CAPhase 1Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutatedNov 2028
GenSci122–Phase 1Advanced Solid TumorDec 2028
GS3-007a dry suspension
Growth hormone secretagogue
–Phase 1Healthy Adults; Pediatric Growth Hormone DeficiencyNov 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02375620SomatropinPhase 2Short Stature Children Born Small for Gestational Age (SGA)OtherDec 2023
NCT04576104Megestrol AcetatePhase 2Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial NeoplasiaOncologyAug 2025
NCT06449027LeuprolidePhase 3Breast Cancer SubjectsOncologyNov 2025
NCT07008417CabergolinePhase 1HyperprolactinemiaMetabolic and endocrineFeb 2026
NCT06189495Genakumab injectionPhase 2Systemic Sclerosis Associated Interstitial Lung DiseaseImmunologyMar 2026
NCT07473570GS3-007a dry suspensionPhase 1Healthy AdultsOtherMay 2026
NCT07040930GenSci120 150 mgPhase 1Rheumatoid ArthritisImmunologyJul 2026
NCT07323329SomatropinPhase 2InfertilityGenitourinaryNov 2026
NCT07043322CabergolinePhase 2Gynecologic DiseaseOtherNov 2026
NCT07124221CabergolinePhase 3HyperprolactinemiaMetabolic and endocrineNov 2026
NCT07016802GenSci134Phase 1SafetyMetabolic and endocrineNov 2026
NCT07338487Megestrol AcetatePhase 1Locally Advanced Cervical CancerOncologyDec 2026
NCT02288962CabergolinePhase 3Pituitary NeoplasmsOncologyDec 2026
NCT05355272SomatropinPhase 2Gulf War SyndromeMetabolic and endocrineDec 2026
NCT07685210GenSci144 tabletsPhase 1PhenylketonuriaMetabolic and endocrineDec 2026
NCT07260500PEG-rhGH Injection (Jintrolong®)Phase 2Short Stature Children Born Small for Gestational Age (SGA)OtherDec 2026
NCT05447208SomatropinPhase 3Preimplantation Genetic TestingMetabolic and endocrineDec 2026
NCT07243379Megestrol AcetatePhase 4Clinical Characteristics and Treatment Outcomes of Malignant Tumor CachexiaOncologyDec 2026
NCT07537231[14C]GS1-144Phase 1Healthy Postmenopausal WomenMetabolic and endocrineDec 2026
NCT07663838GenSci142Phase 1RandomizedInfectious diseaseJan 2027
NCT07366866GenSci136Phase 1Autoimmune DiseaseImmunologyFeb 2027
NCT04867317SomatropinPhase 3Adult Growth Hormone DeficiencyNeurologyFeb 2027
NCT05316493Megestrol AcetatePhase 2Atypical Endometrial HyperplasiaMetabolic and endocrineFeb 2027
NCT03671811Megestrol AcetatePhase 2Atypical Endometrial HyperplasiaOncologyFeb 2027
NCT07286656GenSci098Phase 1SafetyMetabolic and endocrineMar 2027
NCT07691125SomatropinPhase 4Short Bowel Syndrome (SBS) in AdultsGastroenterologyApr 2027
NCT07476586GenSci161Phase 1Healthy VolunteersOtherMay 2027
NCT06998758Megestrol AcetatePhase 3Neoadjuvant ChemotherapyMetabolic and endocrineMay 2027
NCT06500234Megestrol AcetatePhase 3Nutrition DisordersOncologyMay 2027
NCT05913427Megestrol AcetatePhase 2Adrenocortical CarcinomaOncologyJun 2027
NCT07150663Megestrol AcetatePhase 3Non-small Cell Lung CancerOncologyJun 2027
NCT07463235CabergolinePhase 3ProlactinomaOncologyAug 2027
NCT06569758GenSci098Phase 1SafetyOphthalmologySep 2027
NCT07423533GenSci120 150 mgPhase 2Rheumatoid ArthritisImmunologySep 2027
NCT07423533GenSci120 150 mgPhase 2Rheumatoid ArthritisImmunologySep 2027
NCT07423533GenSci120 150 mgPhase 2Rheumatoid ArthritisImmunologySep 2027
NCT07796789Megestrol AcetatePhase 3Nasopharyngeal Cancinoma (NPC)OncologySep 2027
NCT07547995GenSci048Phase 2UveitisOphthalmologyDec 2027
NCT06908434GenSci128Phase 1Solid Tumors Harboring a TP53 Y220C MutationOncologyDec 2027
NCT07319429Megestrol AcetatePhase 2Endometrial CancerOncologyDec 2027
NCT06103513SomatropinPhase 3Growth DisordersMetabolic and endocrineJan 2028
NCT07492160CabergolinePhase 2PregnancyOtherFeb 2028
NCT07072910CabergolinePhase 2MigraineNeurologyMar 2028
NCT07072910CabergolinePhase 2MigraineNeurologyMar 2028
NCT07251166GenSci140Phase 1Advanced Solid TumorsOncologyMar 2028
NCT05681299SomatropinPhase 4HealthyMetabolic and endocrineApr 2028
NCT06963177GenSci048Phase 2Endometriosis-related PainGenitourinaryMay 2028
NCT07230977GenSci139Phase 1Advanced Solid TumorsOncologyJul 2028
NCT07036003SomatropinPhase 1Knee Osteoarthritis (Knee OA)ImmunologyJul 2028
NCT05382637SomatropinPhase 2Growth DisordersMetabolic and endocrineSep 2028
NCT07252414GenSci143 for injectionPhase 1Advanced Solid TumorsOncologyOct 2028
NCT07407504GenSci145Phase 1Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutatedOncologyNov 2028
NCT06772415GenSci122Phase 1Advanced Solid TumorOncologyDec 2028
NCT07543536Megestrol AcetatePhase 3Advanced/Metastatic Breast CancerOncologyApr 2029
NCT07045935CabergolinePhase 4ProlactinomaOncologyDec 2029
NCT03255694SomatropinPhase 2DwarfismMetabolic and endocrineJun 2030
NCT07436793Megestrol AcetatePhase 2Endometrial Endometrioid AdenocarcinomaOncologyJun 2030
NCT07264595GS3-007a dry suspensionPhase 1Pediatric Growth Hormone DeficiencyMetabolic and endocrineNov 2030
NCT07831902Megestrol AcetatePhase 3Endometrial CancerOncologyDec 2030

Targets

DRD2 (1) GHR (1) CXCL10 (1) PGR (1) FOLR1 (1) SLC6A19 (1) TP53 (1) PIK3CA (1) GH1 (1) GNRHR (1) EGFR (1) HER2 (1)

Companies with the same targets

AbbVie Prilenia Vanda Pharmaceuticals Intra-Cellular Therapies LB Pharmaceuticals Sichuan Kelun Pharmaceutical Gedeon Richter Jazz Pharmaceuticals Serina Therapeutics Boryung Pharmaceutical

Companies built like this

Hangzhou Zhongmei Huadong Pharmaceutical Jiangsu Hansoh Pharmaceutical Yuhan Haisco Pharmaceutical Group Sichuan Baili Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.